Last updated: February 23, 2026
What is the Drug with NDC 47335-0892?
NDC 47335-0892 specifies Vasopressin Injection, USP. It is a synthetic form of the natural hormone vasopressin, used mainly for managing vasodilatory shock and diabetes insipidus.
Market Overview
The vasopressin market encompasses several formulations, primarily intravenous (IV) and subcutaneous. It is a niche but critical segment within the broader cardiovascular and emergency drug categories.
Market Size and Growth
- The global vasopressin market was valued at approximately $300 million in 2022.
- It is projected to grow at a compound annual growth rate (CAGR) of 4-6% through 2027.
- Growth drivers include increasing incidence of shock, rising use in vasodilatory shock, and expanding applications in clinical settings.
Major Market Players
| Company |
Product Names |
Market Share (2022) |
Notes |
| Ferring Pharmaceuticals |
Vasostrict |
65% |
Leading supplier globally |
| Pfizer |
Vasopressin Injection (off-label) |
20% |
Limited official distribution |
| Others |
Various regional products |
15% |
Margin varies, less significant |
Regulatory Landscape
- US FMDA approved Vasostrict for vasodilatory shock.
- Other countries’ approvals vary; in some regions, compounded formulations dominate.
Price Analysis
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per 10 Units |
Notes |
| 2020 |
$320 |
Early stage of market stability |
| 2022 |
$340 |
Slight increase from prior years |
| 2023 |
$355 |
Rising due to supply constraints |
Current Pricing for NDC 47335-0892
- The wholesale acquisition cost (WAC) for packaged doses typically ranges from $34 to $36 per 1 mL vial.
- Packaging: Usually supplied in 1 mL vials, with 10 vials per carton, priced around $340 to $360 per carton.
Market Dynamics Affecting Prices
- Price increases are driven by manufacturing costs and regulatory compliance expenses.
- Supply chain disruptions, notably during and post-COVID-19, have caused price volatility.
- Market consolidation reduces competitive pressure, stabilizing prices.
Price Projections (Next 3–5 Years)
| Year |
Projected WAC per 10 vials |
Rationale |
| 2024 |
$360–$370 |
Slight increase; high demand in critical care settings |
| 2025 |
$370–$380 |
Continued inflation; ongoing supply chain issues |
| 2026 |
$380–$390 |
Consolidation in supply chain; improved manufacturing efficiency |
| 2027 |
$390–$400 |
Stabilization; replacement therapies could influence prices |
Competitive Dynamics
The market could experience shifts due to:
- Introduction of biosimilar vasopressin products.
- Regulatory changes permitting broader indications.
- Price competition minimized by limited manufacturers.
Key Takeaways
- NDC 47335-0892 corresponds to Vasopressin Injection, a vital emergency drug.
- The global market remains under $350 million but is steadily growing.
- The product’s price is around $340 to $360 per carton as of 2023.
- Prices are projected to increase gradually, reaching $390 to $400 by 2027.
- Market concentration is high, with Ferring Pharmaceuticals holding a significant share.
FAQs
1. How does the pharmacoeconomic value of vasopressin influence pricing?
Pharmacoeconomic considerations are limited; however, its critical emergency use justifies premium pricing in hospital settings.
2. Are biosimilars threatening the vasopressin market?
Yes. Several biosimilar candidates are under development or approval, which could pressure prices and market share.
3. What regulation impacts pricing for NDC 47335-0892?
FDA approval status and formulary inclusion influence price setting; price controls are limited in the US.
4. How does supply chain disruption affect market stability?
Disruptions increase costs and cause price volatility, especially during pandemic-related manufacturing delays.
5. What are the main cost drivers for vasopressin?
Manufacturing complexity, regulatory compliance costs, and supply chain logistics.
References
[1] MarketsandMarkets. (2022). Vasopressin market analysis.
[2] FDA. (2022). Vasopressin injection approval and labeling details.
[3] IQVIA. (2023). Prescription drug price and volume trends.
[4] Statista. (2023). Emergency drug market size and forecasts.
[5] Ferring Pharmaceuticals. (2023). Vasostrict product information.
